Introduction
pulmonary embolism, thrombosis, bleeding, thrombo-embolic, cancer, VTED, digestive cancer, venous thrombosis
PULMONARY EMBOLISM, THROMBOSIS, BLEEDING, DEEP VEIN THROMBOSIS (DVT), BLOOD CLOTS, VENOUS THROMBOEMBOLIC DISEASE, CANCER, EVENT, DIGESTIVE CANCER, VENOUS THROMBOSIS, POSTOPERATIVE THROMBOSIS, BSE
Venous thromboembolic disease (VTED) refers to a condition characterized by the formation of blood clots within the veins, commonly has two main clinical presentations: deep vein thrombosis (DVT) and/or pulmonary embolism (PE) [The high risk of postoperative thrombosis is due to the combination of two risk factors: cancer and major surgery [Several prospective randomized studies conducted in the early 1980s and late 1990s showed that thromboprophylaxis reduces the risk of thrombosis compared to no prophylaxis or placebo [Over the years, several molecules have been introduced on the market: unfractionated heparin (UFH), low molecular weight heparin (LMWH), vitamin K antagonist (VKA) and direct oral anticoagulants (DOACs). Several guidelines have recommended LMWH or UFH in major abdominopelvic surgery in the absence of bleeding risk [LMWH has advantages over UFH such as a longer half-life and predictable bioavailability [Several biosimilar versions of LovenoxThis study aimed to compare a Biosimilar Enoxaparin [BSE] with Branded Enoxaparin [BE] in patients undergoing digestive cancer surgery in the prevention of venous thrombosis in the postoperative period, to compare the safety of the two treatments and to identify the factors predictive of thrombo-embolic event.